Aim Bulletin
Director dealings: Gfinity CEO ups stake
Gfinity revealed on Monday that chief executive David Halley had acquired 200. 0m ordinary shares in the AIM-listed eSports business.
Sosandar signs lease in Cardiff for fourth store
Women’s fashion brand Sosandar announced the signing of a lease for its fourth store on Monday, in Cardiff's St David's shopping centre.
Futura Medical due $5m milestone payment from Haleon
Futura Medical, the consumer healthcare company behind Eroxon, announced on Monday that a $5m milestone payment had been triggered under its agreement with consumer products giant Haleon.
Cora reports positive analysis results from Tambir gold anomaly
Cora Gold reported positive results from multi-element analysis on Monday, following its recent reconnaissance drilling programme at the Tambor gold anomaly in the Madina Foulbé exploration permit area, eastern Senegal.
Corero Network Security Q3 new orders total $6m
Cybersecurity firm Corero Network Security said on Monday that it has experience continued new customer momentum in Q3, with total orders in the quarter reaching $6. 0m.
Serabi releases updated Coringa economic assessment
Serabi Gold released an updated preliminary economic assessment (PEA) for its wholly-owned Coringa Gold Project in Brazil’s Para state on Monday, including improved project economics.
Vast Resources now expecting sales proceeds later in October
Mining company Vast Resources updated the market on its short-term funding situation on Monday, saying that it now expected to receive proceeds from sales around the third week of October, helping to address its immediate financial requirements.
Solid State wins 'two significant contracts' in US defence sector
Value-added components supplier Solid State has been awarded "two significant contracts" with a combined value of $5. 1m from two leading defence prime contractors for battery packs to be used in the US defence sector.
hVIVO upbeat on positive human challenge trial results with client
Specialist contract research organisation hVIVO announced positive results from a phase 2a human challenge trial (HCT) for Enanta Pharmaceuticals' RSV antiviral candidate, EDP-323, on Monday.
FD Technologies agrees £230m sale of First Derivative business
FD Technologies announced an agreement to sell its First Derivative business to EPAM Systems on Monday, for £230m.